As used in KRS 217.5401 to 217.5408:
(1) "Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, protein other than a chemically synthesized polypeptide, allergenic product or analogous product, or arsphenamine or derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings;
(2) "Device" has the same meaning as in KRS 217.015;
(3) "Drug" has the same meaning as in KRS 217.015;
(4) "Eligible patient" means an individual who meets the requirements of KRS 217.5403;
(5) "Health care provider" means a licensed physician, a licensed advanced practice registered nurse, or a licensed physician assistant;
(6) "Health facility" has the same meaning as in KRS 216B.015;
(7) "Investigational drug, biological product, or device" means a drug, biological product, or device that:
(a) Has successfully completed Phase I of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration; and (b) Remains under investigation in a United States Food and Drug Administration-approved clinical trial;
(8) "Terminal illness" means a progressive disease or a medical or surgical condition that:
(a) Entails significant functional impairment;
(b) Is not considered by a treating health care provider to be reversible even with administration of a treatment currently approved by the United States Food and Drug Administration; and (c) Without life-sustaining procedures, will result in death; and (9) "Written informed consent" means a written document that meets the requirements of KRS 217.5404.